Plain-English translation of NCT07013474 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to treat COVID-19 in people with severely weakened immune systems. Researchers want to learn whether this medication works better when given alone, combined with another antiviral drug called , or if alone is best. The medication is taken as a pill by mouth, while is given through an IV infusion.
People with severely weakened immune systems often have a harder time fighting off COVID-19 and are at higher risk for serious illness and long-lasting infections. This trial is designed to find out whether this new treatment could help protect this vulnerable group more effectively than current options.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three groups: one group receives the new medication plus an IV infusion, another group receives the new medication plus a placebo infusion, and a third group receives a placebo pill plus the IV infusion. You will take the pill twice daily by mouth and receive IV infusions daily at the clinic. Over 24 weeks, you'll have about 10 study visits that include blood work, nasal swabs (some done at home), questionnaires, and clinic check-ins to monitor how you're doing.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
United States